Felldin Marie, Friman Styrbjörn, Olausson Michael, Bäckman Lars, Castedal Maria, Larsson Bo, Henriksson Bengt-Ake, Siewert-Delle Annica
Enheten för transplantation och leverkirurgi, Sahlgrenska Universitetssjukhuset, Göteborg.
Lakartidningen. 2003 Nov 20;100(47):3836-8, 3841.
Acute hepatic failure (AHF) is a life threatening condition with a high mortality rate. There is a need to buy time, either waiting for the liver to regenerate or waiting for urgent liver transplantation. Different modalities of "liver dialysis" have been used during the last decades but of no true success. However, a new technique has been developed called the MARS (Molecular Adsorbent Recycling System) built upon the same principle as haemodialysis but with the capacity to also remove albumin bound compounds thought to be toxic to the liver. This is a report of our ten first cases, all having AHF and considered for liver transplantation. The survival rate was 7/10 and of the 5 patients in need of 5 or more treatments all but one survived. In these cases the MARS-treatment seemed to have positive effects on the course and outcome of the disease but there are a need for controlled trials to clearly prove the benefit of the treatment.
急性肝衰竭（AHF）是一种危及生命的疾病，死亡率很高。需要争取时间，要么等待肝脏再生，要么等待紧急肝移植。在过去几十年里，人们使用了不同形式的“肝脏透析”，但都没有真正成功。然而，一种名为MARS（分子吸附再循环系统）的新技术已经开发出来，它基于与血液透析相同的原理，但也能够去除被认为对肝脏有毒的与白蛋白结合的化合物。这是我们对首批10例病例的报告，所有病例均为急性肝衰竭且考虑进行肝移植。存活率为7/10，在需要接受5次或更多次治疗的5名患者中，除1人外全部存活。在这些病例中，MARS治疗似乎对疾病的病程和结局有积极影响，但需要进行对照试验以明确证明该治疗的益处。
